Interdisciplinary Center for Health Technology Assessment and Public Health (IZPH)
What we are
In societies with demographic shift and budget constraints, the greatest challenges in health care – especially for the German Health Care System – are the efficient provision of health care services, quality improvement, and cost reduction. Solving those socially important challenges requires multi-professional outcomes research.
The Interdisciplinary Center for Health Technology Assessment and Public Health (IZPH) of the FAU is the first thematically inter-professional German research platform on Health Outcomes Research across faculties of the FAU. It was founded in 2001 and systematically merges scientific insights from the three Faculties of Medicine, of Engineering, and of Business, Economics, and Law. Central aims of the IZPH are the scientific-oriented and evidence-based political consulting using population and registry data as well as an analysis of health care under everyday conditions (“real-world evidence”).
Outcomes Research/ Health Services Research
Every day, there are about 890 new diagnoses of dementia and about 590 new diagnoses of stroke in Germany. Those numbers are vividly illustrating the huge importance of both widespread diseases, dementia and stroke, in health politics and their consequences for the social security system in Germany. Population-based registries for the purpose of Outcomes Research of dementia and stroke are therefore the scientific focus of the IZPH, according to the slogan, ‘you can only manage what you measure’.
Health Technology Assessment
In Germany, a growing number of people get injured or die due to dangerous implanted medical devices and prostheses. In 2017 alone, in total 14,000 injuries, deaths and other problems related to medical devices were reported. Usually, the recall of medical devices or announcements of security warnings are left to the manufacturers themselves instead of being carried out by public authorities. Since 2010, there are about 1,000 recalls per year and three per day on average, initiated by manufacturers. In the same time, there were only six recalls mandated by public authorities. Implant registries are therefore required in order to secure sustainably and effectively citizens of defective medical devices, in particular dangerous implants and prostheses. In cooperation with the leading-edge cluster Medical Valley EMN, the IZPH is analyzing the requirements regarding the structure and content of implant registries in order to secure the safety of citizens. Concepts of quality assurance, transparency of data, public reporting and aspects of an independent funding of implant registries are prioritized. The work and publications of the IZPH regarding implant registries had an impact on the draft legislation „Entwurf eines Gesetzes zur Errichtung eines Deutschen Implantateregisters (Implantateregister-Errichtungsgesetz – EDIR)“ of the Federal Ministry of Health (BMG), published in January 2019.
For the first time ever, the German health expenditures exceeded the threshold of 1 billion euros per day in 2017. According to Destatis, the health expenditures amounted to 374 billion euros in total for the year 2017, which is s share of 11.3% of the gross domestic product. The high increase occurred in particular due to high health care costs for chronic diseases. In respect to the demographic development in Germany, associated with an ageing of the population, a further increase of health care costs in the area of age-related diseases can be expected. On the one hand, the IZPH is therefore focusing on cost-of-illness studies of widespread diseases with high public health relevance, such as dementia, stroke, and heart failure. In Germany, the annual costs of the widespread disease heart failure are about 23,000 euros per patient, the lifetime costs are about 113,000 euros per patient. Those studies are fundamental for the health care planning of payers, service Providers, and health care politicians. On the other hand, the IZPH is doing health economic evaluations of pharmacological and non-pharmacological treatments. Furthermore, novel methodological approaches are explored in order to provide a transparent display of the benefit of innovative health technologies and in order to facilitate a comprehensible and balanced reimbursement decision for the actors of the conjoint self-administration in the German health care system (G-BA, GKV-Spitzenverband).